August 25, 2022
FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO TALQUETAMAB FOR RELAPSED/REFRACTORY MYELOMA
The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody.